Safety & Tolerability Study of CTP-499 in Patients With Moderate Chronic Kidney Disease

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

August 31, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Stage 3 Chronic Kidney Disease

Interventions

DRUG

CTP-499

"3 X 200 mg tablets (QD for 2 weeks)~3 x 200 mg tablets (BID for 2 weeks)"

DRUG

placebo

tablets

Trial Locations (3)

West Coast Clinical Trials, Costa Mesa

Southern California Clinical Research, Garden Grove

Orange County Research Center, Tustin